Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A WT-1 and PRAME "Fast-DC" Immunotherapy As a Potential Post-Remission Strategy for AML

Yngvar Floisand, MD PhD, Iris Bigalke, MD, Dag Josefsen, MD PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Richard Addo, MD PhD, Dolores J. Schendel, PhD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-139255

Published: 2020

Journal Articles

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Judith Eckl, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Petra Prinz-Schulz, PhD, Christiane Fingerhut, Yngvar Floisand, MD PhD, Dag Josefsen, Iris Bigalke, MD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD, Dolores Schendel, Prof., Anna Tafuri, MD

Blood (2019) 134 (Supplement_1): 3923.

https://doi.org/10.1182/blood-2019-129749

Published: 2019

Journal Articles

Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use

Iris Bigalke, MD, Judith Eckl, PhD, Guri Solum, MSc, Kirsti Hønnåshagen, Msc, Lisbeth Skoge, MSc, Yngvar Fløisand, MD PhD, Dag Josefsen, MD PhD, Stein Sæbøe-Larssen, PhD, Christiane Geiger, PhD, Dolores Schendel, PhD, Gunnar Kvalheim, MD PhD

Blood (2018) 132 (Supplement 1): 2718.

https://doi.org/10.1182/blood-2018-99-114557

Published: 2018

Journal Articles

Poor Mobilizing Lymphoma Patients Rescued By Addition of Plerixafor during Stem Cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose Therapy with Autologous Stem Cell Support

Dag Josefsen, MD PhD, Yngvar Fløisand, MD PhD, Harald Holte, Jr., MD PhD, Gunnar Kvalheim, MD PhD

Blood (2016) 128 (22): 5826.

https://doi.org/10.1182/blood.V128.22.5826.5826

Published: 2016

Journal Articles

The Use Of Plerixafor In Hard-To-Mobilize Lymphoma and Multiple Myeloma Patients Not Only Provide Sufficient Numbers Of Pbpcs To Proceed To High Dose Therapy, But Also Have a Positive Impact On Survival

Dag Josefsen, MD, PhD, Geir Hetland, MD, PhD, Yngvar Fløisand, MD, Ph.D, Harald Holte, MD, PhD, Gunnar Kvalheim, MD, PhD

Blood (2013) 122 (21): 5517.

https://doi.org/10.1182/blood.V122.21.5517.5517

Published: 2013

Journal Articles

Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells

Blood (2013) 122 (21): 4195.

https://doi.org/10.1182/blood.V122.21.4195.4195

Published: 2013

Journal Articles

Selective inhibition of cell death in malignant vs normal B-cell precursors: implications for cAMP in development and treatment of BCP-ALL

Elin Hallan Naderi, Hege Katrin Ugland, Phoi-Phoi Diep, Dag Josefsen, Ellen Ruud, Soheil Naderi, Heidi Kiil Blomhoff

Blood (2013) 121 (10): 1805–1813.

https://doi.org/10.1182/blood-2012-08-452698

Published: 2013

Includes: Supplemental data

Journal Articles

Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

Blood (2011) 118 (21): 784.

https://doi.org/10.1182/blood.V118.21.784.784

Published: 2011

Journal Articles

The Proportion of Ph+ CD34 + CD38 neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study

Blood (2010) 116 (21): 667.

https://doi.org/10.1182/blood.V116.21.667.667

Published: 2010

Journal Articles

Human Bone Marrow Mononuclear Cells, CD34+ Cells and CD133+ Cells Do Not Form Vascular Structures in Vivo

Dag Josefsen, MD, PhD, Axel Kuchler, Mengyu Wang, Guttorm Haraldsen, Gunnar Kvalheim

Blood (2008) 112 (11): 5453.

https://doi.org/10.1182/blood.V112.11.5453.5453

Published: 2008

Journal Articles

Characterisation of Side Population (SP) Cells Obtained from Different Hematopoietic Progenitor/Stem Cell Compartments in Human Bone Marrow and Peripheral Blood.

Dag Josefsen, MD, PhD, Lise Forfang, Marianne Dyrhaug, Gunnar Kvalheim, MD, Ph.D

Blood (2006) 108 (11): 4170.

https://doi.org/10.1182/blood.V108.11.4170.4170

Published: 2006

Journal Articles

Phenotypic Examination of Side Population (SP) Cells in Highly Enriched Human CD34+ Cells Obtained from Peripheral Blood Progenitor Cells (PBPC) and Bone Marrow.

Dag Josefsen, MD, Ph.D, Leiv S. Rusten, MD, Ph.D, Trond Stokke, Ph.D, Lise Forfang, Erlend B. Smeland, MD, Ph.D, Gunnar Kvalheim, MD, Ph.D

Blood (2004) 104 (11): 4140.

https://doi.org/10.1182/blood.V104.11.4140.4140

Published: 2004

Journal Articles

Protein kinase C-α isoform is involved in erythropoietin-induced erythroid differentiation of CD34 + progenitor cells from human bone marrow

June Helen Myklebust, Erlend B. Smeland, Dag Josefsen, Mouldy Sioud

Blood (2000) 95 (2): 510–518.

https://doi.org/10.1182/blood.V95.2.510

Published: 2000

NARROW

A WT-1 and PRAME "Fast-DC" Immunotherapy As a Potential Post-Remission Strategy for AML

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use

Poor Mobilizing Lymphoma Patients Rescued By Addition of Plerixafor during Stem Cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose Therapy with Autologous Stem Cell Support

The Use Of Plerixafor In Hard-To-Mobilize Lymphoma and Multiple Myeloma Patients Not Only Provide Sufficient Numbers Of Pbpcs To Proceed To High Dose Therapy, But Also Have a Positive Impact On Survival

Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells

Selective inhibition of cell death in malignant vs normal B-cell precursors: implications for cAMP in development and treatment of BCP-ALL

Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

Human Bone Marrow Mononuclear Cells, CD34+ Cells and CD133+ Cells Do Not Form Vascular Structures in Vivo

Characterisation of Side Population (SP) Cells Obtained from Different Hematopoietic Progenitor/Stem Cell Compartments in Human Bone Marrow and Peripheral Blood.

Phenotypic Examination of Side Population (SP) Cells in Highly Enriched Human CD34+ Cells Obtained from Peripheral Blood Progenitor Cells (PBPC) and Bone Marrow.

Protein kinase C-α isoform is involved in erythropoietin-induced erythroid differentiation of CD34 + progenitor cells from human bone marrow

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only